The present invention relates to a novel fused bicyclic heteroaryl derivative or a pharmacologically acceptable salt thereof, which has an excellent hypoglycemic effect or treats and/or prevents the onset of a disorder of carbohydrate or lipid metabolism or a disease mediated by peroxisome proliferator-activated receptor (PPAR) γ.
A compound having the general formula (I):
wherein
R
1
represents a C
1
-C
6
alkyl group, a C
6
-C
10
aryl group which may be substituted with 1 to 5 group(s) independently selected from Substituent Group a, or the like; R
2
represents a C
1
-C
6
alkyl group; R
3
represents a C
6
-C
10
aryl group which may be substituted with 1 to 5 group(s) independently selected from Substituent Group a, or the like; Q represents a group represented by the formula ═CH— or a nitrogen atom; and Substituent Group a represents a halogen atom, a C
1
-C
6
alkyl group, a C
1
-C
6
hydroxyalkyl group, and the like, or a pharmacologically acceptable salt thereof.